Symbols

AXGN

Axogen·NASDAQ

--(--)

AXGN fundamentals

AXGN Q4 2025 Earnings

Axogen (AXGN) released its earnings on Feb 24, 2026: revenue was 59.90M (YoY +21.25%), beat estimates; EPS was 0.07 (YoY 0.00%), missed estimates.

Revenue / YoY

59.90M

+21.25%

EPS / YoY

0.07

0.00%

Report date

Feb 24, 2026

AXGN Earnings Call Summary for Q4,2025

Revenue Growth: 2025 revenue up 20.2% to $225.2M, EBITDA +41% to $27.9M.
FDA Breakthrough: Avance becomes first FDA-approved nerve repair biologic with 12-year exclusivity.
2026 Guidance: ≥18% revenue growth ($265.7M+), 74-76% gross margin, free cash flow positive.
Market Expansion: 130 extremities reps by end-2026, 30 breast reps, 100+ prostate procedures in 2025.
Margin Dynamics: 2026 gross margin pressure from biologic transition, 2027+ improvement via scale.

Earnings

EPS

Revenue

Revenue & Expenses

AXGN has released its 2025 Q4 earnings report, with revenue of 59.90M, reflecting a YoY change of 21.25%, and net profit of -13.16M, showing a YoY change of -3023.56%. The Sankey diagram below clearly presents AXGN's revenue sources and cost distribution.

Key Indicators

Axogen (AXGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Axogen (AXGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Axogen (AXGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Axogen (AXGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown